Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm5Tyj mutation
(1 available);
any
Trp53 mutation
(232 available)
|
|
|
cellular
|
|
• marked genetic instability similar to that seen in Trp53tm1Tyj homozygous cells
|
|
|
• similar to Trp53 null cells, the percentage of cells in S phase is increased compared to wild-type cells
|
|
|
• in the absence of cre, MEFs are refractory to stress-induced cell death
(J:96433)
• lack cell-culture-induced senescence
(J:118233)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm5Tyj mutation
(1 available);
any
Trp53 mutation
(232 available)
|
|
|
cellular
|
N |
• infection with adenoviral cre restores normal DNA damage-induce G1 arrest response and stress-induced apoptotic responses
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1.1Hbji mutation
(0 available);
any
Kras mutation
(76 available)
Trp53tm5Tyj mutation
(1 available);
any
Trp53 mutation
(232 available)
|
|
|
cellular
|
|
• MEFs treated with adeno-cre and later with tamoxifen
• increased cell proliferation
• more cells at the G2/M phase of the cell cycle
• foci formation in 3D cell culture after tamoxifen treatment
• withdrawal of tamoxifen reduces colony formation
|
neoplasm
|
|
• mice treated with adeno-cre at 6-8 weeks of age and tamoxifen starting three weeks later
• tamoxifen doses of 100ug/mouse, 250ug/mouse, or 1000ug/mouse resulted in no lung abnormalities
• the intermediate dose of 500ug/mouse results in lung hyperplasia starting after 5 weeks of treatment
• lung adenomas found after 8 weeks of treatment
• tamoxifen treatment discontinued after 12 weeks and lung hyperplasia is decreased a weeks later
• lungs are normal 2 weeks after discontinuation of tamoxifen treatment
|
respiratory system
|
|
• mice treated with adeno-cre at 6-8 weeks of age and tamoxifen starting three weeks later
• tamoxifen doses of 100ug/mouse, 250ug/mouse, or 1000ug/mouse resulted in no lung abnormalities
• the intermediate dose of 500ug/mouse results in lung hyperplasia starting after 5 weeks of treatment
• lung adenomas found after 8 weeks of treatment
• tamoxifen treatment discontinued after 12 weeks and lung hyperplasia is decreased a weeks later
• lungs are normal 2 weeks after discontinuation of tamoxifen treatment
|
neoplasm
|
|
• mice with radiation-induced tumors that are subsequently treated with tamoxifen show tumor regression (7 of 10) or cessation of tumor progression (2 of 10)
|
mortality/aging
|
|
• animal succumb due to tumor burden at 20-24 weeks
|
neoplasm
|
|
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
|
|
|
• develop in alveoli and near the bronchioalveolar duct junction by 15 weeks of age with tamoxifen administration at 6-8 weeks
• larger bronchioles and non terminal bronchi appear normal
• advanced papillary adenocarcinomas are observed at 21 weeks after tamoxifen treatment
|
respiratory system
|
|
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
|
|
|
• hyperplasia is observed at 3 weeks after tamoxifen induction, and persists at 15 and 21 weeks
|
mortality/aging
|
|
• mice die 14 weeks or less after tamoxifen administration
|
neoplasm
|
|
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
|
|
|
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenocarcinomas in the alveoli by 14 weeks of age
|
respiratory system
|
|
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
|
|
|
• at 2 weeks after tamoxifen treatement, brochioalveolar duct junctions (BADJ) appear normal, but small adenomas occur in the alveoli; these progress to adenocarcinoma but the BADJ remain histologically normal
|
mortality/aging
|
|
• loss of Trp53 expression does not alter or delay the lethality
|
embryo
|
|
• loss of Trp53 expression does not alter or delay the overall phenotype
|
cellular
|
|
• loss of Trp53 expression does not alter or delay the impairment of cell proliferation
|
Analysis Tools